(Q42639071)

4 November 2017

title

The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy (English)

1 reference

4 November 2017

Sturdee DW

1

1 reference

4 November 2017

Ulrich LG

2

1 reference

4 November 2017

Barlow DH

3

1 reference

4 November 2017

Wells M

4

1 reference

4 November 2017

Campbell MJ

5

1 reference

4 November 2017

Vessey MP

6

1 reference

4 November 2017

Nielsen B

7

1 reference

4 November 2017

Anderson MC

8

1 reference

4 November 2017

Bragg AJ

9

1 reference

4 November 2017

language of work or name

1 reference

1 November 2000

1 reference

BJOG: an International Journal of Obstetrics and Gynaecology

4 November 2017

published in

1 reference

4 November 2017

volume

107

1 reference

4 November 2017

issue

11

1 reference

4 November 2017

page(s)

1392-1400

1 reference

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

Estrogen-progestin replacement therapy and endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

Compliance considerations with estrogen replacement: withdrawal bleeding and other factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

The effects of oestrogens and progestogens on the postmenopausal endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

Combined continuous hormone replacement therapy: a critical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-0528.2000.TB11654.X

10.1111/J.1471-0528.2000.TB11654.X

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference